syndrome. A low blood factor VII level was a pointer to hepatic pathology in one. Whilst similar diagnostic problems may have occurred in one or two other cases, most cases of HSE come to necropsy where Reye's syndrome is easily excluded.
The strong clinical impression is that this is a new disease. The aetiology is obscure. Extensive bacteriological and virological studies have failed to discover a causative agent. Morris (1983) was impressed by a similarity between HSE and the staphylococcal toxic shock syndrome, and proposed that HSE may be attributable to a bacterial toxin. It was also suggested that as maternal IgG protects infants in the first few weeks of life, after this initial period they are vulnerable to an unspecified toxin-producing bacterium (Morris 1983). One of our patients was a 14-day-old (full-term) baby, younger than any reported case, which suggests that the age distribution may not be so restricted. Raised plasma concentrations of immunoreactive trypsin in the face of lowered plasma concentrations of alpha-l-antitrypsin have been reported (Levin et al. 1983 ). It has been suggested that a low alpha-1-antitrypsin may allow circulating immunoreactivetrypsin to cause destruction of the microcirculation, and that this may be important in the pathogenesis of the disease. However, we suspect that the elevated immunoreactive trypsin is probablya nonspecific' feature of renal impairment. The suggestion that the condition is due to heatstroke (Bacon 1983) caused by excessive wrapping of the child (Bacon et al. 1979 ) is supported neither by the only modest elevation of core temperature nor by the absence of history of over-wrapping in most cases.
Epidemiological studies are in progress, and paediatricians in the UK are asked to report cases to the PHLS Communicable Disease Surveillance Centre (61 Colindale Road, London NW9 5EQ). T Argon laser in the treatment of port wine stains' Soon after the first laser was produced by T H Maiman in 1960, it became apparent that the skin provided an excellent test model for the investigation of the effects of laser radiation on living tissues. Research began with the pulsed ruby laser and continued with the argon, carbon dioxide and neodymium YAG lasers which were subsequently developed. A laser (light amplification by stimulated emission of radiation) produces coherent light, an intense beam of pure, collimated monochromatic light, in which all the light waves travel in phase and in the same direction. The lasing medium, which in most medical lasers is a gas, is contained in the laser tube which has, at one end, a fully reflective mirror and, at the other, a partially reflective mirror which allows access to the laser beam. The lasing medium is excited to invert the normal population ratio of excited to non-excited particles which normally has a large excess in the non-excited state. An excited particle will decay to the low-energy ground state with the emission of a photon, a quantum of radiant energy or a light particle. If this photon strikes an excited particle of the lasing medium, it causes it to decay to the ground state and to emit an identical photonstimulated emission. The photons are reflected back into the medium from the mirrors causing further stimulated emission with a rapid build-up of light energy in the laser tubethe cascade effect.
Each laser produces essentially one wavelength of coherent light, which is determined by the lasing medium. The wavelength determines the pattern of absorption of the light when it strikes body tissues and this defines the clinical role of each laser. To change clinical role one must change laser, although there is some overlap in the clinical roles of the three most commonly used lasers.
The carbon dioxide laser is a high precision, bloodless, light scalpel which can be used for the excision or vaporization of lesions, with sealing of blood vessels of up to 0.5 mm in diameter. The neodymium YAG laser is deeply absorbed and can be used for thermal destruction of tissues and for the coagulation of blood vessels. The argon laser produces blue/green coherent light at several wavelengths, but the majority of energy is at 488 and 514 nm. This beam is absorbed by structures with its complementary colour red, but will pass through clear structures without absorption and without thermal damage.
'Paper read to Section of Ophthalmology, 9 February Journal of the Royal Society of Medicine Volume 77 September 1984 723
The first clinical use of the argon laser was in ophthalmology, in which it was used to perform retinal photocoagulation through and without damage to the clear anterior parts of the eye.
In the treatment of a port wine stain, the argon laser beam will pass through the relatively transparent, normal epidermis with minimal absorption and thermal damage and is then absorbed by the haemoglobin in the abnormal network of capillaries in the outer dermis, causing thermal damage and thrombosis. It has been shown histologically by Apfelberg et al. (1979) that the thrombosed vessel layer is replaced by colourless fibrous tissue over a period of months, with a marked reduction in the number of vessels and of the colour of the port wine stain. Although there is some damage to the epidermis, there is no irreversible damage to the secondary skin appendages and the epidermis returns to normal or shows minor atrophic changes.
A port wine stain is thought to occur in between 0.1-0.5% of the population, and it will almost always have a devastating effect on the life of an individual. In the past, many forms of treatment were tried but none gave consistently satisfactory results.
The first report of the use of the argon laser on port wine stains was by Solomon et al. in 1968 and, since then, a large number of papers have appeared. in the literature describing its use in the management of port wine stains and other vascular abnormalities of the skin.
All workers appear to be agreed on certain features of port wine stains that are predictive of a good response. Results appear to be better in older patients, and above the age of 17 a good response can be achieved in 60-80% of patients. Below this age, and particularly below the age of 10, results appear to be less predictable. However, in several of the reported series, very few young children have been treated and this is probably due to the extreme difficulty of treating young patients with facial marks under local anaesthetic. In the Southampton Laser Unit, carefully controlled tests and treatments are being carried out on children down to the age of 4, under local anaesthetic and, where necessary, general anaesthetic, in an attempt to determine the youngest age at which successful treatment can be carried out; some encouraging results are being obtained.
Marks on the face respond better than those on the limbs and trunk, but this is related to the very large area of many of the non-facial marks which makes treatment technically very difficult. Dark purple marks respond better than pale pink or red marks and there is some early, as yet inconclusive, evidence that the carbon dioxide laser may be of value in the management of pale marks. Noe et al. (1980) studied the histology of port wine stains and showed that in those in which a large fraction of the dermis was occupied with vessels, with a high mean vessel area and high filling of vessels with erythrocytes, a good response to argon laser treatment could be expected. They referred to the 'haemoglobin target' of the birth mark. However, Ohmori & Huang (1981) showed that, using a spectrophotometer, the colour of a lesion correlated well with the histological pattern.
Despite prediction, some who should respond well do not and vice versa, and many, workers have described the use of a, test -patch to determine the response of an individual's port wine stain to argon laser treatment. A study of the literature shows a wide range of treatment techniques in both the performance of the test patch and in subsequent treatment. In some series the treatment parameters are not accurately reported; it is essential that these be recorded completely and accurately (Arndt et al. 1981) and that optimal treatment parameters are established (Carruth 1982) .
From a study of the reported incidence of scarring, it appears to be directly related to the total energy delivered and treatment must, therefore, be at the lowest possible power level to achieve the lowest possible incidence of scarring. If treatment results in significant hypertrophic scarring of the mark, it will be more difficult to camouflage and the deformity will have been made worse. To reduce the incidence of scarring below the level of 5% reported by Cosman in 1980, the 'minimal blanching power technique' was developed in the Southampton Laser Unit. First, an area of the mark is anaesthetized with local anaesthetic and suitable eye protection provided for the surgeon and patient. The beam is moved freehand over the area to be tested, using a repeated pulse of 0.2 seconds, and the power is gradually increased in increments of 0.2 watt until a blanched line is produced. The power may be increased further by 0.1-0.2 watt to achieve a uniformly blanched line 1 mm wide. The beam is then used to erase the test patch of about I cm2. A I mm focused spot is used, with the beam kept in focus and at right angles to the skin by the hand-piece attachment described by Carruth (1982) .
As the epidermis is not entirely transparent to argon laser light, it will suffer some damage: the test patch area weeps for a few days and a scab forms which separates after 1-2 weeks, leaving the tested area red. This colour fades until the test patch can be assessed after 6 months and, during this time, the tested area often shows some transient, post-traumatic hyperpigmentation. At the end of six months, one of three results will be found. First, a good response with a satisfactory persistent blanching with a preservation of normal skin texture. In these cases treatment will be performed under local or general anaesthetic. For treatment around the eye, protective contact lenses are available and must be used. Second, the area may still be too pigmented and a further test patch will be performed at a higher power 0.2 watts above the previous test power. If the minimal blanching power technique has been used, a second test patch will be needed in about 20% of patients. Third, the test patch may show hypertrophic or atrophic scarring, but an incidence of less than 2% should be achieved with the minimal blanching power technique. If scarring does occur in an adult, treatment will not be possible but if it occurs in a child, further testing will be carried out after a few years.
In the performance of treatment a wide range of powers have been used but most workers use an exposure time of 0.2 seconds, with an automatically repeated pulse. However, there is an increasing tendency to use a 'continuous' beam attempting to move it with an 'air brush' technique over the skin at uniform speed. There appears to be no greater incidence of scarring and the technique is certainly much quicker than with an intermittent pulse of light. However, accurate recordings of dosage levels, etc., are not possible with this technique.
Debate continues on the technique of erasure. Some state that the laser imprints must touch and others that they should overlap. With the freehand technique using the beam to achieve clinical blanching, there will inevitably be some overlap. In the Southampton Unit the actual area treated, as measured by spot area times the number of exposures, is about 1.5 times the measured treated area.
Whichever technique is used, most workers use the beam to 'block out' the mark, but Apfelberg et al. (1983) have described the zebra-stripe technique, leaving 1 mm untreated stripes between similar, treated stripes to achieve better epidermal regeneration. The untreated stripes are then treated after healing has taken place.
When treatment is carried out free-hand it is both tedious and fatiguing and to treat a 'half face' birth mark takes several hours. A computercontrolled robot arm is being developed to treat the large areas automatically and areas around the nose, mouth and eyes will then be treated by hand. The time-scale of a treatment programme is also very long. At the time of the initial consultation a test patch is performed and this is assessed after six months, when treatment will be begun. After one area has been treated, a wait of 2-3 months is thought necessary to ensure that there are no unexpected adverse effects when the larger area is treated, and so treatment may take some months. Although a preliminary result can be judged at six months, the mark will continue to fade for up to 15 months. Cosman (1982) has shown that if a minimal blanching power technique has been used, retreatment can be carried out on areas not adequately lightened, with further improvement and no significant incidence of scarring, if the retreatment is performed more than one year after the original treatment.
Patients must be told clearly what to expect, as many believe that the mark will disappear completely and are disappointed to be told to expect a marked lightening with preservation of normal skin texture. If the skin has developed nodularity, which often occurs with age, the argon laser treatment will flatten the nodules and achieve an improvement in the texture of the skin. However, as treatment proceeds and the patient can see the blanching, the initial disappointment diminishes and a 'satisfied patient' can be achieved in those with a good prognosis in 60-80% of cases. Further research will define the optimum treatment parameters and the youngest age at which treatment can be carried out. The argon laser has become the treatment of choice for the port wine stain and other vascular malformations of the skin, and further research will improve the satisfactory results which are already being obtained. J A S Carruth Consultant Otolaryngologist Southampton University Hospitals
